文献速递前列腺癌

如何攻克转移性前列腺癌的「冷」免疫微环境

How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-04-05

本综述检索PubMed、Google Scholar和Cochrane数据库,探讨前列腺癌肿瘤微环境的免疫抑制机制及免疫治疗策略。前列腺癌微环境通过调节性T细胞、肿瘤相关巨噬细胞、髓源性抑制细胞(MDSC)、细胞因子及腺苷产生等机制高度免疫抑制,多数单靶点免疫治疗试验临床疗效有限,未来需整合患者筛选与联合治疗以克服多重耐药机制。

要点

  • 前列腺癌微环境高度免疫抑制,呈「冷肿瘤」表型。
  • 腺苷和TGF-beta是潜在免疫治疗靶点。
  • 单靶点免疫治疗疗效有限,需联合多机制治疗。

核心结论

  • 前列腺癌固有地产生多种免疫抑制机制,单一免疫治疗难以克服,需策略性联合多种疗法以增强临床活性。

研究设计与样本

  • 综述,检索PubMed、Google Scholar和Cochrane数据库获取前列腺癌免疫相关文献。

主要发现

  • 前列腺癌相关肿瘤微环境高度免疫抑制,原因包括调节性T细胞、肿瘤相关巨噬细胞和髓源性抑制细胞(MDSC)的功能。
  • 肿瘤基质细胞和成纤维细胞分泌的细胞因子环境以及前列腺酸性磷酸酶产生腺苷也参与免疫抑制。
  • 腺苷和肿瘤生长因子beta(TGF-beta)是强效免疫抑制分子,也可能是潜在治疗靶点。
  • 多数前列腺癌免疫治疗试验仅针对单一免疫抑制机制,临床疗效有限。

临床怎么用

  • 未来免疫治疗需整合改进的患者筛选,并采用联合疗法针对多种耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced prostate cancer remains one of the most common and deadly cancers, despite advances in treatment options. Immunotherapy has provided little benefit to a majority of patients, largely due to the immunosuppressive tumor microenvironment that gives rise to inherently "cold tumors". In this review, we discuss the immunopathology of the prostate tumor microenvironment, strategies for treating prostate cancer with immunotherapies, and a perspective on potential approaches to enhancing the efficacy of immunotherapies. METHODS: Databases, including PubMed, Google Scholar, and Cochrane, were searched for articles relevant to the immunology of prostate cancer. We discuss the impact of different types of treatments on the immune system, and potential mechanisms through which prostate cancer evades the immune system. RESULTS: The tumor microenvironment associated with prostate cancer is highly immunosuppressive due to (1) the function of regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSCs), (2) the cytokine milieu secreted by tumor stromal cells and fibroblasts, and (3) the production of adenosine via prostatic acid phosphatase. Both adenosine and tumor growth factor beta (TGF-beta) serve as potent immunosuppressive molecules that could also represent potential therapeutic targets. While there have been many immunotherapy trials in prostate cancer, the majority of these trials have targeted a single immunosuppressive mechanism resulting in limited clinical efficacy. Future approaches will require the integration of improved patient selection as well as use of combination therapies to address multiple mechanisms of resistance. CONCLUSION: Prostate cancer inherently gives rise to multiple immunosuppressive mechanisms that have been difficult to overcome with any one immunotherapeutic approach. Enhancing the clinical activity of immunotherapies will require strategic combinations of multiple therapies to address the emerging mechanisms of tumor immune resistance.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33820953. doi:10.1038/s41391-021-00340-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。